SCHEMBL10176581

SCHEMBL10176581

c1cc2c(nc3n2CCN(C2CCC2)CC3)c2c1CCCC2

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
KDM2B Q8NHM5 4/20 0.35
HRH3 Q9Y5N1 9/20 0.34
KDM4E B2RXH2 4/20 0.34
CYP2D6 P10635 3/20 0.33
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
SIGMAR1 Q99720 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422518 0.85 HRH3 (0.36) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL418538 0.81 MAPT (0.41) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL420834 0.78 ESR1 (0.39) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL7886698 0.75 MAPT (0.42) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL10176584 0.73 MAPT (0.42) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL420832 0.72 MAPT (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1345907 0.72 MAPT (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL10176823 0.72 MAPT (0.49) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL7893655 0.72 MAPT (0.47) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL419622 0.71 MAPT (0.45) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 US disclosed
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2012-01-26 US disclosed
US-8063032-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 ALDH1A1 2598/4885MAPT 738/4885SMN1; SMN2 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.